ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: TH-PO0807

Delayed Presentation of IgG4-Related Disease and Subsequent Lymphoma in Phospholipase A2 Receptor (PLA2R)(-) Membranous Nephropathy

Session Information

Category: Glomerular Diseases

  • 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics

Authors

  • Fong, Jie Ming Nigel, Sengkang General Hospital, Singapore, Singapore
  • Guo, Weiwen, Sengkang General Hospital, Singapore, Singapore
  • Tong, Tong, Singapore General Hospital, Singapore, Singapore
  • Wong, Kye Ling, Singapore General Hospital, Singapore, Singapore
  • Yeoh, Lee Ying, Sengkang General Hospital, Singapore, Singapore
Introduction

Membranous nephropathy (MN) is associated with autoimmune disease and malignancy. Renal manifestations of IgG4-related disease (IgG4-RD) include tubulointerstitial nephritis (TIN), MN, and obstructive uropathy from retroperitoneal fibrosis. We present a case of PLA2R(-) MN which developed features of IgG4-RD 4 years later and lymphoma after 6 years.

Case Description

A 49-year-old man presented with microscopic haematuria, 2g/day proteinuria, and creatinine (Cr) 0.9mg/dL. Renal biopsy was classical for MN, without TIN. Serum and tissue PLA2R was negative. Workup for secondary MN, including CT urogram, was negative. He was treated as low-risk PLA2R(-) primary MN with lisinopril.

4 years later, repeat CT displayed bilateral ureteric thickening. 4 ureteroscopies were normal; biopsy showed benign urothelium without plasma cells or fibrosis. Serum IgG4 (23.7g/L [0.04-0.86]) and IgG4/IgG ratio (0.62 [<0.4]) were high. IgG4 stain on the earlier renal biopsy and serum protein electrophoresis were unremarkable. Patient declined PET-CT or more invasive biopsies. Multidisciplinary consensus favoured IgG4-RD. As he was well with normal Cr and urine protein/creatinine ratio (UPCR) 0.4-0.9g/g, steroids were not given.

6 years from MN diagnosis, he developed acute kidney injury and an enlarged submandibular gland, biopsy of which found diffuse large B cell lymphoma on a chronic inflammatory background with >100/hpf IgG4+ plasma cells and IgG4/IgG ratio >0.5. PET-CT revealed advanced disease. He was given rasburicase for spontaneous tumor lysis, then polatuzumab, rituximab, cyclophosphamide, doxorubicin, and prednisolone chemoimmunotherapy. He responded with ~50% decrease in size of lymph nodes, submandibular gland, and retroperitoneal soft tissue in 3 months, normalisation of Cr (0.7mg/dL) and UPCR (0.1g/g).

Discussion

This case highlights the need for continued vigilance for secondary causes of PLA2R(-) MN, even with negative initial screen. IgG4-RD is a diagnostic challenge, as IgG4 levels are nonspecific, and retroperitoneum is inaccessible for biopsy. We postulate that immune dysregulation in IgG4-RD may increase lymphoma risk. In this case, the submandibular gland, commonly involved in IgG4-RD, retained IgG4-rich features at DLBCL diagnosis. Alternatively, he may have had indolent lymphoma mimicking IgG4-RD, which transformed into DLBCL.

Digital Object Identifier (DOI)